Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Least Shorted S&P 500 Stocks in August
Executive Reshuffles: LLY, S and RY Companies in Focus
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Pfizer's "weight gain drug" has achieved positive experimental results and is expected to fill the current situation of "no available drugs" in the fatal disease course.
① Unlike weight loss drugs, pfizer monoclinal antibody drug ponegromab aims to reduce factors that suppress appetite in the brain; ② In the field of cancer, about 80% of patients are diagnosed with cachexia and are expected to die within a year. ③ So far, the FDA has not approved any drugs for the treatment of cachexia.
"Florida Discourages Use Of MRNA Covid Vaccines In Older Adults; In Updated Guidance To Health Care Providers, Florida Health Officials Advise That "Non-mRNA Covid-19 Vaccines And Treatment" Should Be Prioritized" - NBC News
AstraZeneca, Roche Cut at Deutsche After Trial Readouts for Key Drugs
Novavax COVID-19 Vaccines Now Available
Eli Lilly Analyst Ratings
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
Today's Morning Movers and Top Ratings | ADBE, ORCL, MRNA and More
Technology stocks led the S&P to four consecutive gains, Oracle reached a new high after hours, the US dollar and US bonds fell, gold hit a new high, and commodities rose.
In August, the PPI in the United States showed a cooling down of inflation, and the market slightly raised its bets on the Fed's aggressive interest rate cuts. US stocks rose together, with Nvidia up nearly 2%, while NIO Inc and XPeng fell more than 5%. The European Central Bank cut interest rates for the second time this year, but maintained a restrictive policy. European bonds fell, and the euro rebounded from its four-week low. Commodities rose across the board, with US oil briefly rising by 3.7%, gold reaching a new high with a nearly 2% increase, palladium rising by over 4%, and copper experiencing its largest two-month increase.
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Looking At Eli Lilly's Recent Unusual Options Activity
Noom Launches Cheaper Compounded Version of Novo's Semaglutide
Each U.S. State Has at Least 20% of Adults Living With Obesity: CDC
Morgan Stanley Announces Its 15 'Vintage Values' Names of 2025
Eli Lilly and Co invested $1.8 billion in Ireland to expand the production capacity of weight loss and Alzheimer's disease drugs.
Eli Lilly and Co will invest $1.8 billion in two production bases in Ireland to promote the production of its popular weight loss drugs, diabetes drugs, and Alzheimer's disease drugs. Eli Lilly and Co will also use the new factory to produce new drugs under development.
US stock market closing: Bullish layers are stacked, Nasdaq staged a "deep V takeoff", Donald Trump concept stocks injured alone.
①Harris' favorable election situation led the pv concept stocks, with First Solar leading the S&P 500 index; ②Production cut rumors stimulated a sharp rise in the lithium sector; ③Russia considers restricting exports of certain strategic raw materials, leading to a collective increase in uranium producers; ④Trump's media technology fell more than 10%, hitting a new low after landing in the US stock market.